Barbara Ann Karmanos Cancer Institute

This study tests a device called TheraBionic P1 that sends low-level electromagnetic fields to the body. It is for people with advanced hormone-positive, HER2-negative breast cancer who have already tried standard treatments. The goal is to see if the device can help control the …

This study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic canc…

This early-phase study tests whether adding metformin (a common diabetes drug) to standard chemotherapy or immunotherapy is safe for people with advanced solid tumors. About 60 participants will take metformin alone for two weeks, then continue it alongside their regular cancer t…

This phase 2 trial tests whether dapagliflozin, a diabetes drug, is safe and can lower high urine protein levels in people with renal AL amyloidosis—a rare condition where abnormal proteins damage the kidneys. About 20 participants will take the drug daily for 6 months and be mon…

This phase 2 trial tests whether a combination of iberdomide (a pill) and daratumumab (an injection) can eliminate leftover cancer cells in multiple myeloma patients who still have minimal residual disease after a stem cell transplant. About 60 participants will receive up to 26 …

This pilot study is testing whether a device called TheraBionic P1, which delivers targeted electromagnetic fields, can affect breast cancer tumors before surgery. About 24 women with early-stage, hormone receptor-positive, HER2-negative breast cancer will use the device three ti…

This study tests a device called TheraBionic P1 in people with advanced liver cancer who have already tried at least two other treatments or cannot take standard therapy. The goal is to see if the device can help them live longer and improve their quality of life. About 198 adult…

This study tests whether adding a non-invasive device that delivers low-level radio waves (AM RF EMF) to the targeted drug fruquintinib can help people with metastatic colorectal cancer that has stopped responding to other treatments live longer. About 102 participants will recei…

This early study tests a special PET/CT scan that uses a modified tryptophan molecule to make tumors light up more clearly than normal tissue. About 24 adults with brain, breast, neuroendocrine, or rectal cancers will get one scan to see if this method helps doctors tell tumors a…

This study is testing whether a 12-week high-intensity functional training program, like CrossFit, can improve movement, body composition, and quality of life in cancer survivors. Researchers will enroll 500 adult cancer survivors who have been cleared by their doctor. The goal i…

This study tests a special ink called Magic Ink that is only visible under UV light, used to mark the skin for daily radiation treatment in breast cancer patients. The goal is to see if it is as safe and effective as standard permanent tattoo ink, while being less noticeable. Thi…

This study tests a brochure called ASQ-CT that helps patients ask their doctors better questions about clinical trials. About 293 adults with cancer, heart disease, or neurological conditions will use the brochure before a doctor visit. Researchers want to see if it makes patient…

This pilot trial is testing whether amyloidosis patients can use the MyFitnessPal smartphone app to track their daily food and supplement intake for 8 weeks. The goal is to see if this low-cost method is feasible for studying malnutrition and weight loss in this condition. Forty …

This study aims to help African American cancer survivors learn about and get genetic testing for hereditary cancer risks. Researchers are adapting an online educational program to be culturally relevant, with input from community leaders and genetics experts. About 85 participan…